T
Tao Wu
Researcher at China Three Gorges University
Publications - 12
Citations - 712
Tao Wu is an academic researcher from China Three Gorges University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 356 citations.
Papers
More filters
Journal ArticleDOI
Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography.
Kang Zhang,Xiaohong Liu,Jun Shen,Zhihuan Li,Ye Sang,Xingwang Wu,Yunfei Zha,Wenhua Liang,Chengdi Wang,Ke Wang,Linsen Ye,Ming Gao,Zhongguo Zhou,Liang Li,Jin Wang,Zehong Yang,Huimin Cai,Jie Xu,Lei Yang,Wenjia Cai,Wenqin Xu,Shaoxu Wu,Wei Zhang,Shanping Jiang,Lianghong Zheng,Xuan Zhang,Li Wang,Liu Lu,Jiaming Li,Haiping Yin,Winston Wang,Oulan Li,Charlotte Zhang,Liang Liang,Tao Wu,Ruiyun Deng,Kang Wei,Yong Zhou,Ting Chen,Johnson Y.N. Lau,Manson Fok,Jianxing He,Tianxin Lin,Weimin Li,Guangyu Wang +44 more
TL;DR: Using a large computed Tomography database from 4,154 patients, an AI system is developed that can diagnose NCP and differentiate it from other common pneumonia and normal controls and is made available globally to assist the clinicians to combat COVID-19.
Journal ArticleDOI
Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
Xuan Zhang,Tao Wu,Xinyi Cai,Jianhua Dong,Cuifeng Xia,Yongchun Zhou,Rong-Yao Ding,R. Yang,Jing Tan,Lijuan Zhang,Ya Zhang,Yuqin Wang,Chao Dong,Yunfeng Li +13 more
TL;DR: This review of immunotherapy for CRC covers diagnosis and treatment, clinical prognostic characteristics, the mechanism of nIT, analysis of completed prospective and retrospective studies, and ongoing clinical trials, and the clinical practice of using nIT for MSI-H/dMMR LACRC.
Journal ArticleDOI
Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study
Xuan Zhang,R. Yang,Tao Wu,Xinyi Cai,Guoyu Li,Kun Yu,Yong Li,Rong Ding,Chao Dong,Jinshan Li,Ruixi Hu,Qing Feng,Yunfeng Li +12 more
TL;DR: Neoadjuvant monoimmunotherapy with PD-1 inhibitor has favorable ORR and pCR rate, and relatively low incidences of irAEs and srAEs for patients with dMMR/MSI-H LACRC, suggesting that this nIT regimen of single-agent PD- 1 inhibitor is significantly effective and sufficiently safe.
Journal ArticleDOI
Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis
TL;DR: IGF2BP3 was confirmed as an independent prognostic signature in COAD patients and might be a therapeutic target in this study and could be used in personalized immunotherapy for COAD.
Journal ArticleDOI
Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability
Tao Wu,Xuan Zhang,Xinxing Liu,Xinyi Cai,Tao Shen,Ding-Guo Pan,Rong Ding,Ruixi Hu,Jianhua Dong,Jinshan Li,Lin Xie,Shichao Geng,Zhaoyu Yang,Lu Xing,Yunfeng Li +14 more
TL;DR: In this paper , the authors used scRNA-seq to assess differences among microenvironment components between therapy-resistant and therapy-sensitive groups in metastatic colorectal cancer (mCRC) patients with first-line anti-programmed cell death protein-1 (PD-1) monotherapy.